Articles By Jack Cush, MD
RWCS 2016 – Periodic Fever and Macrophage Activation Syndrome + Pregnancy in IBD
Pregnancy and Immune Modulating Therapies
Read Article
Lupus Flares After Renal Transplant
Whether lupus activity is ameliorated by end-stage renal disease (ESRD) or transplantation has been debated.
Read Article
Patient's Out-of-Pocket Costs for New Drugs Sky-Rocketing
The good news: in 2015 the FDA approved a record number of new drugs (n=45). The bad news: most new drugs entering the market today have an exorbitantly high price tag.
Read Article
RWCS 2016 - Updates in AS, PsA and Lupus
Update on Ankylosing Spondylitis and Spondyloarthritis
Read Article
Smoking and Age Linked to Development of Inflammatory Arthritis
A prospective cohort of RA first-degree relatives were prospectively studied for genetic and environmental factors (smoking, body mass index, education, and parity) and RA-related autoantibodies that may influence future development of inflammatory joint symptoms over a 2 year 
Read Article
Prescribers More Likely to Escalate to Biologics than Triple DMARD Therapy
The paradigm for DMARD use in rheumatoid arthritis (RA) begins with DMARD monotherapy and then escalates to combination therapy with either DMARDs or a combination of conventional DMARD plus a biologic DMARD (bDMARD).
Read Article
RWCS 2016 – OA/OP, Gout, Sarcoid & JIA Reviewed
Recent Developments in Osteoarthritis, Osteoporosis and Gout
Read Article
RWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana
The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13. Rheumatoid Arthritis Year in Review
Read Article
What To Do After Teriparatide?
Once the clock runs out on teriparatide (TPTD or Forteo), what is the next best option?
Read Article
Rheumatoid Modern Management is Better but More Costly
The mantra of rheumatologists worldwide is to treat rheumatoid arthritis (RA) earlier and more aggressively. While referral of early RA patients has improved, there is little data demonstrating that more aggressive treatment works or is cost effective.
Read Article
